Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination antiretroviral therapy regimen consisting of four drugs used for the treatment of HIV-1 infection. It combines two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) with two protease inhibitors (indinavir and ritonavir). This combination therapy works by inhibiting different stages of the HIV replication cycle, with zidovudine and lamivudine inhibiting the reverse transcriptase enzyme, while indinavir and ritonavir inhibit the viral protease enzyme. The combination has shown effectiveness in suppressing HIV viral load and increasing CD4 cell counts in patients with HIV infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zidovudine + lamivudine + indinavir + ritonavir.